Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -42.52% is 38% above its 3-year average of -68.65%, around the middle of its 3-year range (-130.63%–47.91%).
126.89% below its 12-month average of -18.74%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -28.12%.
GROSS MARGIN
-42.52%
GROSS MARGIN AVG TTM
-18.74%
GROSS MARGIN AVG 3Y
-63.50%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-126.89%
CURRENT VS 3Y AVG
+33.04%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.44%
median of 752 covered companies
CURRENT VS SECTOR MEDIAN
-207.81%
vs the sector median at left
Market Cap
$5.91B
Gross Margin
98.58%
TTM Avg
95.46%
3Y Avg
84.33%
5Y Avg
82.16%
Market Cap
$5.90B
Gross Margin
97.23%
TTM Avg
60.83%
3Y Avg
-170.72%
5Y Avg
-113.81%
Market Cap
$5.74B
Gross Margin
54.49%
TTM Avg
70.12%
3Y Avg
77.23%
5Y Avg
64.22%
Market Cap
$6.31B
Gross Margin
89.00%
TTM Avg
89.73%
3Y Avg
89.61%
5Y Avg
73.24%
Market Cap
$5.68B
Gross Margin
-15.02%
TTM Avg
-3561.64%
3Y Avg
-7339.64%
5Y Avg
-5851.73%
Market Cap
$5.53B
Gross Margin
53.85%
TTM Avg
55.16%
3Y Avg
56.69%
5Y Avg
56.69%
Market Cap
$6.51B
Gross Margin
60.14%
TTM Avg
62.77%
3Y Avg
60.62%
5Y Avg
54.58%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.01B | -42.52% | -18.74% | -63.50% | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 98.58% | 95.46% | 84.33% | 82.16% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | 97.23% | 60.83% | -170.72% | -113.81% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 54.49% | 70.12% | 77.23% | 64.22% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.31B | 89.00% | 89.73% | 89.61% | 73.24% |
| CG Oncology Inc. (CGON)vs › | $5.68B | -15.02% | -3561.64% | -7339.64% | -5851.73% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | 53.85% | 55.16% | 56.69% | 56.69% |
| RadNet, Inc. (RDNT)vs › | $5.53B | 9.70% | 9.04% | 10.84% | 11.30% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 60.14% | 62.77% | 60.62% | 54.58% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.51B | 39.32% | 37.08% | 36.51% | 35.71% |
Gross Margin
-42.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -28.12% |
| 2026-03-31 | 47.91% |
| 2025-12-31 | -25.54% |
| 2025-09-30 | -37.94% |
| 2025-06-30 | -50.01% |
| 2025-03-31 | -62.60% |
| 2024-12-31 | -41.74% |
| 2024-09-30 | -77.60% |
| 2024-06-30 | -56.03% |
| 2024-03-31 | -81.99% |
| 2023-12-31 | -61.50% |
| 2023-09-30 | -130.63% |
| 2023-06-30 | -108.32% |
| 2023-04-02 | -130.40% |
